TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to wide adoption of its flagship Alzheimer's disease treatment.
Pharmaceuticals
Biogen partner Eisai cut US jobs. Now can it boost Alzheimer's drug sales?
Japanese drugmaker aims for faster, easier adoption of Leqembi
A patient takes part in a clinical trial for the Alzheimer's drug lecanemab.(Eisai)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
